Meito  Sangyo  Co., Ltd. Logo

Meito Sangyo Co., Ltd.

Produces food products and specialty chemicals for industrial and pharmaceutical applications.

2207 | T

Overview

Corporate Details

ISIN(s):
JP3920200007
LEI:
Country:
Japan
Address:
名古屋市西区笹塚町2丁目41番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Meito Sangyo Co., Ltd. is a diversified company primarily engaged in the manufacture and sale of food and chemical products, alongside a real estate business. The company's Food Division produces a variety of goods, including confectionery, beverages, seasonings, and food additives. Its Fine Chemicals Division specializes in creating unique products, such as polysaccharides (notably Dextrans) and enzymes, through microbial fermentation and chemical synthesis. These high-quality chemical products are supplied to various industries for applications including feed additives and pharmaceutical ingredients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 01:48
Registration Form
確認書
Japanese 9.5 KB
2025-11-13 01:46
Interim Report
半期報告書-第84期(2025/04/01-2026/03/31)
Japanese 239.5 KB
2025-11-06 02:10
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.0 KB
2025-09-24 04:43
Major Shareholding Notification
訂正報告書(大量保有報告書・変更報告書)
Japanese 33.6 KB
2025-09-22 09:56
Major Shareholding Notification
大量保有報告書
Japanese 38.3 KB
2025-06-27 03:00
Regulatory News Service
臨時報告書
Japanese 26.6 KB
2025-06-25 06:14
Governance Information
内部統制報告書-第83期(2024/04/01-2025/03/31)
Japanese 26.1 KB
2025-06-25 06:12
Registration Form
確認書
Japanese 9.1 KB
2025-06-25 06:11
Registration Form
有価証券報告書-第83期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 01:22
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 01:21
Interim Report
半期報告書-第83期(2024/04/01-2025/03/31)
Japanese 226.5 KB
2024-07-16 09:13
M&A Activity
臨時報告書
Japanese 23.4 KB
2024-06-27 05:22
Post-Annual General Meeting Information
臨時報告書
Japanese 26.6 KB
2024-06-27 02:18
Governance Information
内部統制報告書-第82期(2023/04/01-2024/03/31)
Japanese 24.6 KB
2024-06-27 02:16
Registration Form
確認書
Japanese 9.1 KB

Automate Your Workflow. Get a real-time feed of all Meito Sangyo Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Meito Sangyo Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Meito Sangyo Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.